Kenneth J Livak
Overview
Explore the profile of Kenneth J Livak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
21143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Maurer K, Park C, Mani S, Borji M, Penter L, Jin Y, et al.
bioRxiv
. 2024 Feb;
PMID: 38405900
Understanding how intra-tumoral immune populations coordinate to generate anti-tumor responses following therapy can guide precise treatment prioritization. We performed systematic dissection of an established adoptive cellular therapy, donor lymphocyte infusion...
12.
Penter L, Borji M, Nagler A, Lyu H, Lu W, Cieri N, et al.
Nat Commun
. 2024 Jan;
15(1):32.
PMID: 38167262
Single-cell transcriptomics has become the definitive method for classifying cell types and states, and can be augmented with genotype information to improve cell lineage identification. Due to constraints of short-read...
13.
Parry E, Lemvigh C, Deng S, Dangle N, Ruthen N, Knisbacher B, et al.
Cancer Cell
. 2023 Sep;
41(10):1803-1816.e8.
PMID: 37738974
Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response,...
14.
Bachireddy P, Azizi E, Burdziak C, Nguyen V, Ennis C, Maurer K, et al.
Cell Rep
. 2023 Aug;
42(8):113011.
PMID: 37556329
No abstract available.
15.
Penter L, Liu Y, Wolff J, Yang L, Taing L, Jhaveri A, et al.
Blood
. 2023 Jan;
141(15):1817-1830.
PMID: 36706355
The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026...
16.
Parry E, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh S, et al.
Nat Med
. 2023 Jan;
29(1):158-169.
PMID: 36624313
Richter syndrome (RS) arising from chronic lymphocytic leukemia (CLL) exemplifies an aggressive malignancy that develops from an indolent neoplasm. To decipher the genetics underlying this transformation, we computationally deconvoluted admixtures...
17.
Ten Hacken E, Yin S, Redd R, Hernandez Sanchez M, Clement K, Hoffmann G, et al.
Blood Adv
. 2022 Dec;
7(16):4514-4517.
PMID: 36477552
No abstract available.
18.
Penter L, Ten Hacken E, Southard J, Lareau C, Ludwig L, Li S, et al.
Cancer Res
. 2022 Dec;
83(5):667-672.
PMID: 36469010
Significance: mtDNA mutations can serve as natural barcodes to enable lineage tracing in murine cancer models, which can be used to provide new insights into disease biology and to identify...
19.
Ten Hacken E, Sewastianik T, Yin S, Hoffmann G, Gruber M, Clement K, et al.
Blood Cancer Discov
. 2022 Dec;
4(2):150-169.
PMID: 36468984
Significance: Mouse models reflective of the genetic complexity and heterogeneity of human tumors remain few, including those able to recapitulate transformation to aggressive disease histologies. Herein, we model CLL transformation...
20.
Liu S, Iorgulescu J, Li S, Borji M, Barrera-Lopez I, Shanmugam V, et al.
Immunity
. 2022 Oct;
55(10):1940-1952.e5.
PMID: 36223726
T cells mediate antigen-specific immune responses to disease through the specificity and diversity of their clonotypic T cell receptors (TCRs). Determining the spatial distributions of T cell clonotypes in tissues...